Harrison N Jones1, Maragatha Kuchibhatla2, Kelly D Crisp3, Lisa D Hobson Webb4, Laura Case5, Milisa T Batten6, Jill A Marcus6, Richard M Kravitz7, Priya S Kishnani8. 1. Department of Surgery, Division of Head and Neck Surgery & Communication Sciences, Duke University Medical Center, Durham, NC, USA; Department of Speech Pathology and Audiology, Duke University Medical Center, Durham, NC, USA. Electronic address: harrison.jones@duke.edu. 2. Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA. 3. Department of Surgery, Division of Head and Neck Surgery & Communication Sciences, Duke University Medical Center, Durham, NC, USA. 4. Department of Neurology, Neuromuscular Division, Duke University Medical Center, Durham, NC, USA. 5. Division of Physical Therapy, Duke University School Of Medicine, Durham, NC, USA. 6. Department of Speech Pathology and Audiology, Duke University Medical Center, Durham, NC, USA. 7. Division of Pediatric Pulmonary and Sleep Medicine, Duke University Medical Center, Durham, NC, USA. 8. Department of Pediatrics, Division of Medical Genetics, Duke University Medical Center, Durham, NC, USA.
Abstract
INTRODUCTION:Morbidity and mortality in adults with late-onset Pompe disease (LOPD) results primarily from persistent progressive respiratory muscle weakness despite treatment with enzyme replacement therapy (ERT). To address this need, we have developed a 12-week respiratory muscle training (RMT) program that provides calibrated, individualized, and progressive pressure-threshold resistance against inspiration and expiration. Our previous results suggest that our RMT regimen is safe, well-tolerated, and results in large increases in respiratory muscle strength. We now conduct an exploratory double-blind, randomized control trial (RCT) to determine: 1) utility and feasibility of sham-RMT as a control condition, 2) the clinically meaningful outcome measures for inclusion in a future efficacy trial. This manuscript provides comprehensive information regarding the design and methods used in our trial and will aid in the reporting and interpretation of our future findings. METHODS:Twenty-eight adults with LOPD will be randomized (1:1) in blocks of 4 to RMT (treatment) or sham-RMT (control). Assessments will be conducted at pretest, posttest, 3-months detraining, and 6-months detraining. The primary outcome is maximum inspiratory pressure (MIP). Secondary outcomes include maximum expiratory pressure (MEP), 6-min walk test (6MWT), Gait, Stairs, Gowers, and Chair test (GSGC), peak cough flow (PCF), and patient-reported life activity/social participation (Rasch-built Pompe-specific Activity scale [R-Pact]). Exploratory outcomes include quantitative measures from polysomnography; patient reported measures of fatigue, daytime sleepiness, and sleep quality; and ultrasound measures of diaphragm thickness. This research will use a novel tool to provide automated data collection and user feedback, and improve control over dose. ETHICS AND DISSEMINATION: The results of this clinical trial will be promptly analyzed and submitted for publication. Results will also be made available on clinicaltrials.gov. ClinicalTrials.gov: NCT02801539, R21AR069880.
RCT Entities:
INTRODUCTION: Morbidity and mortality in adults with late-onset Pompe disease (LOPD) results primarily from persistent progressive respiratory muscle weakness despite treatment with enzyme replacement therapy (ERT). To address this need, we have developed a 12-week respiratory muscle training (RMT) program that provides calibrated, individualized, and progressive pressure-threshold resistance against inspiration and expiration. Our previous results suggest that our RMT regimen is safe, well-tolerated, and results in large increases in respiratory muscle strength. We now conduct an exploratory double-blind, randomized control trial (RCT) to determine: 1) utility and feasibility of sham-RMT as a control condition, 2) the clinically meaningful outcome measures for inclusion in a future efficacy trial. This manuscript provides comprehensive information regarding the design and methods used in our trial and will aid in the reporting and interpretation of our future findings. METHODS: Twenty-eight adults with LOPD will be randomized (1:1) in blocks of 4 to RMT (treatment) or sham-RMT (control). Assessments will be conducted at pretest, posttest, 3-months detraining, and 6-months detraining. The primary outcome is maximum inspiratory pressure (MIP). Secondary outcomes include maximum expiratory pressure (MEP), 6-min walk test (6MWT), Gait, Stairs, Gowers, and Chair test (GSGC), peak cough flow (PCF), and patient-reported life activity/social participation (Rasch-built Pompe-specific Activity scale [R-Pact]). Exploratory outcomes include quantitative measures from polysomnography; patient reported measures of fatigue, daytime sleepiness, and sleep quality; and ultrasound measures of diaphragm thickness. This research will use a novel tool to provide automated data collection and user feedback, and improve control over dose. ETHICS AND DISSEMINATION: The results of this clinical trial will be promptly analyzed and submitted for publication. Results will also be made available on clinicaltrials.gov. ClinicalTrials.gov: NCT02801539, R21AR069880.
Keywords:
Late-onset Pompe disease; Maximum expiratory pressure; Maximum inspiratory pressure; Pompe disease; Randomized control trial; Respiratory muscle training
Authors: M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger Journal: Eur Respir J Date: 2005-08 Impact factor: 16.671
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: H Sánchez Riera; T Montemayor Rubio; F Ortega Ruiz; P Cejudo Ramos; D Del Castillo Otero; T Elias Hernandez; J Castillo Gomez Journal: Chest Date: 2001-09 Impact factor: 9.410
Authors: Rosa Capozzo; Vitaliano N Quaranta; Fabio Pellegrini; Andrea Fontana; Massimiliano Copetti; Pierluigi Carratù; Francesco Panza; Anna Cassano; Vito A Falcone; Rosanna Tortelli; Rosa Cortese; Isabella L Simone; Onofrio Resta; Giancarlo Logroscino Journal: J Neurol Date: 2014-12-19 Impact factor: 4.849
Authors: Edward J Cupler; Kenneth I Berger; Robert T Leshner; Gil I Wolfe; Jay J Han; Richard J Barohn; John T Kissel Journal: Muscle Nerve Date: 2011-12-15 Impact factor: 3.217
Authors: Marloes L C Hagemans; Sabine P M van Schie; A Cecile J W Janssens; Pieter A van Doorn; Arnold J J Reuser; Ans T van der Ploeg Journal: J Neurol Date: 2007-03-02 Impact factor: 4.849
Authors: J Raaphorst; J Tuijp; L Verweij; E J A Westermann; A J van der Kooi; M A Gaytant; L H van den Berg; M de Visser; M J Kampelmacher Journal: Eur J Neurol Date: 2013-02-09 Impact factor: 6.089
Authors: Matthias Boentert; Hélène Prigent; Katalin Várdi; Harrison N Jones; Uwe Mellies; Anita K Simonds; Stephan Wenninger; Emilia Barrot Cortés; Marco Confalonieri Journal: Int J Mol Sci Date: 2016-10-17 Impact factor: 5.923
Authors: Harrison N Jones; Maragatha Kuchibhatla; Kelly D Crisp; Lisa D Hobson-Webb; Laura Case; Milisa T Batten; Jill A Marcus; Richard M Kravitz; Priya S Kishnani Journal: Neuromuscul Disord Date: 2020-09-28 Impact factor: 4.296
Authors: Anna F Fusco; Angela L McCall; Justin S Dhindsa; Lucy Zheng; Aidan Bailey; Amanda F Kahn; Mai K ElMallah Journal: Int J Mol Sci Date: 2020-03-24 Impact factor: 5.923